GleamWall
中文EN

CUE Cue Biopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1645460 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY401.9%
TTM net income YoY-448.5%
TTM EPS YoY-107.1%
Revenue 3-yr CAGR110.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-387.7%
Net margin-579.9%
FCF margin-143.7%
EBITDA margin-384.0%

Returns

ROE-800.4%
ROA-418.0%
ROIC (approx.)—
Asset turnover0.72x

Leverage & solvency

Liabilities / assets42.9%
Debt / equity0.00x
Current ratio3.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-314.6%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$27.47M$9.29M
R&D expense$37.74M$36.30M
SG&A expense$16.24M$14.59M
Operating income-$26.55M-$41.50M
Interest expense$100,000$100,000
Income tax$500,000$0
Net income-$26.60M-$40.67M
EBITDA-$25.59M-$41.10M
EPS (basic)-0.28-0.72
EPS (diluted)-0.28-0.72
Weighted avg. shares (diluted)94.73M56.33M
Banking
Net interest income-$357,000-$796,000
Balance sheet
Cash & equivalents$27.14M$22.46M
Short-term investments—$0
Receivables$5.55M$945,000
Current assets$36.98M$25.14M
PP&E, net$241,000$471,000
Total assets$42.21M$32.19M
Current liabilities$13.49M$13.69M
Short-term debt—$37,000
Long-term debt—$0
Total debt—$37,000
Total liabilities$15.78M$14.69M
Shareholders' equity$26.43M$17.50M
Net debt—-$22.42M
Shares outstanding3.22M61.82M
Cash flow statement
Operating cash flow-$21.69M-$36.33M
Capital expenditure$177,000$66,000
Free cash flow-$21.86M-$36.40M
Investing cash flow$75,000$32,000
Financing cash flow$26.29M$10.24M
Depreciation & amortization$958,000$397,000
Stock-based compensation$4.74M$6.85M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.